Shanghai Longwood Biopharmaceuticals raised hundreds of millions of RMB in its Series B+ financing round to advance its innovative drug pipelines, with support from notable investors including Qiming Venture Partners.
Target Company Overview
Shanghai Longwood Biopharmaceuticals Co., Ltd., hereafter referred to as "Longwood Biopharmaceuticals," has successfully completed its Series B+ financing round, raising hundreds of millions of RMB. Founded in 2012 by Dr. Zhe Wang, a prominent figure in chemical drug research and development, the company focuses on the independent R&D of innovative drugs that are First-in-class (FIC) and Best-in-class (BIC), holding global intellectual property rights aimed at addressing unmet clinical needs. Currently, Longwood Biopharmaceuticals boasts nearly 100 invention patents, including over 30 PCT international patents.
Dr. Zhe Wang is a National Special Expert and has over 30 years of experience in drug development, having been mentored by Professor E.J. Corey, a Nobel laureate in Chemistry at Harvard University. His extensive background spans the entire industrial chain from project initiation to drug commercialization, leading to significant advancements in new drug R&D for anti-infection, anti-viral, and anti-cancer treatments.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
In China, the biopharmaceutical industry has been experiencing significant growth fueled by increased investment in R&D and an expanding healthcare market. The demand for innovative therapeutics continues to rise, than
Similar Deals
Qiming Venture Partners
invested in
Longwood Biopharmaceuticals
in 2025
in a Series B deal